posted on 2022-07-05, 08:07authored byRichard J Allen, Beatriz Guillen-Guio, Emma Croot, Luke M Kraven, Samuel Moss, Iain Stewart, R Gisli Jenkins, Louise V Wain
<p>Coronavirus disease 2019 (COVID-19) is an infectious disease potentially leading to long lasting respiratory symptoms and has resulted in over 4 million deaths worldwide. Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease (ILD) characterised by an aberrant response to alveolar injury leading to progressive scarring of the lungs. Individuals with ILD are at a higher risk of death from COVID-19 [1] </p>
Funding
Action for Pulmonary Fibrosis Mike Bray Research Fellowship